The impact of sofosbuvir/velpatasvir/voxilaprevir treatment on serum hyperglycemia in hepatitis C virus infections: a systematic review and meta-analysis.

ABSTRACT:

Background

The combination of Sofosbuvir (SOF), velpatasvir (VEL), and voxilaprevir (VOX) is an effective, safe rescue therapy for patients with previous treatment failure. Direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection in diabetics with a history of hypoglycemia could improve insulin resistance due to HCV clearance. However, some studies have shown that SOF/VEL/VOX causes grade 3 hyperglycemia and other adverse events, which contradicts the findings of other DAA studies.

Aim

To analyze the incidence of grade 3 hyperglycemia of SOF/VEL/VOX for chronic HCV infection.

Methods

We searched electronic databases from the inception of each database until October 2021. A random-effects model was employed to pool data. The study was conducted acc

SUBMITTER: Hung HY 

PROVIDER: S-EPMC9858431 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature